ArticleOncoTargets and therapy2026
The Expression and Oncogenic Role of NTSR2 in Human Glioblastoma.
Article in OncoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Neurotensin receptor 2 (NTSR2) plays critical pro-tumor roles in multiple human solid tumors. However, the expression characteristics, biological function and molecular mechanism of NTSR2 in glioblastoma (GBM) remain poorly elucidated. Methods: Bioinformatics analysis was used to analyze NTSR2 expression and its clinical prognostic significance in GBM. NTSR2 expression in glioma tissues was validated by immunohistochemistry, Western blot (WB) and RT-qPCR, while immunofluorescence staining detected its subcellular localization. In vitro functional assays were performed to evaluate the effects of NTSR2 on GBM cell proliferation, apoptosis, migration and invasion. The downstream molecules and AKT signaling pathway were verified via bioinformatics tools, WB and RT-qPCR. A mouse intracranial xenograft model with in vivo fluorescence imaging was established to validate the tumor-modulating role of NTSR2. Results: NTSR2 was significantly downregulated in glioma tissues and negatively correlated with pathological grade. Functional experiments confirmed that NTSR2 promotes proliferation, migration, invasion and inhibits apoptosis in GBM cells. Mechanistically, NTSR2 activates AKT signaling and modulates the expression of downstream effectors, including Cyclin B1/CDK4, ASCL1, POSTN, proBDNF and Caspase-3. In vivo imaging results further verified that NTSR2 knockdown markedly suppresses intracranial tumor growth. Conclusion: Despite decreased expression in GBM tissues, NTSR2 functions as an oncogenic driver to facilitate GBM malignant progression by activating the AKT signaling pathway and regulating downstream POSTN/proBDNF axes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.